Results 11 to 20 of about 215,570 (267)

Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism

Cardiovascular Diabetology, 2018
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9), a major regulator of cholesterol homeostasis, is associated with glucose metabolism. Liraglutide, a glucagon-like peptide-1 receptor agonist, can increase insulin secretion in a glucose ...
Sheng-Hua Yang, Rui-Xia Xu, Chuan-Jue Cui, Yin Wang, Ying Du, Zhi-Guo Chen, Yu-Hong Yao, Chun-Yan Ma, Cheng-Gang Zhu, Yuan-Lin Guo, Na-Qiong Wu, Jing Sun, Bu-Xing Chen, Jian-Jun Li   +13 more
doaj   +1 more source

Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease

Journal of Translational Medicine, 2018
Background Patients with monogenic familial hypercholesterolemia (FH) have high risk for coronary artery disease (CAD). A recent FH Expert Panel suggested that FH was underdiagnosed and undertreated which needs early diagnosis.
Ye-Xuan Cao, Na-Qiong Wu, Di Sun, Hui-Hui Liu, Jing-Lu Jin, Sha Li, Yuan-Lin Guo, Cheng-Gang Zhu, Ying Gao, Qiu-Ting Dong, Geng Liu, Qian Dong, Jian-Jun Li   +12 more
doaj   +1 more source

Free fatty acids and cardiovascular outcome: a Chinese cohort study on stable coronary artery disease

Nutrition & Metabolism, 2017
Background Studies have revealed that plasma level of free fatty acids (FFAs) is related to cardiovascular disease. However, the role of FFAs in clinical outcomes of stable coronary artery disease (SCAD) has been less evaluated.
Hui-Wen Zhang, Xi Zhao, Yuan-Lin Guo, Cheng-Gang Zhu, Na-Qiong Wu, Jing Sun, Geng Liu, Qian Dong, Jian-Jun Li   +8 more
doaj   +1 more source

Oral Porphyromonas gingivalis and Fusobacterium nucleatum Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia

Biomedicines, 2022
Background: Low-grade chronic inflammation, promoted by dysbiosis of the gut and oral microbiota, has been shown to contribute to individual susceptibility to atherosclerotic cardiovascular disease (ASCVD).
Maria Cristina Curia, Pamela Pignatelli, Domenica Lucia D’Antonio, Damiano D’Ardes, Elena Olmastroni, Luca Scorpiglione, Francesco Cipollone, Alberico Luigi Catapano, Adriano Piattelli, Marco Bucci, Paolo Magni   +10 more
doaj   +1 more source

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy

Journal of Translational Medicine, 2019
Background Proprotein convertase subtilisin/kexin 9 (PCSK9) has been proposed as a novel target for coronary artery disease (CAD). Familial hypercholesterolemia (FH) is characterized by high prevalence of CAD and major cardiovascular events (MACEs ...
Ye-Xuan Cao, Jing-Lu Jin, Di Sun, Hui-Hui Liu, Yuan-Lin Guo, Na-Qiong Wu, Rui-Xia Xu, Cheng-Gang Zhu, Qian Dong, Jing Sun, Jian-Jun Li   +10 more
doaj   +1 more source

Diabetes Dyslipidemia [PDF]

Diabetes Therapy, 2016
Diabetes mellitus is associated with a considerably increased risk of premature atherosclerotic cardiovascular disease. Intensive glycemic control has essentially failed to significantly improve cardiovascular outcomes in clinical trials. Dyslipidemia is common in diabetes and there is strong evidence that cholesterol lowering improves cardiovascular ...
Schofield, Jonathan D, Liu, Yifen, Rao-Balakrishna, Prasanna, Malik, Rayaz A, Soran, Handrean   +4 more
openaire   +2 more sources

Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism [PDF]

Endocrine Connections, 2022
Hypothyroidism is often associated with elevated serum levels of total cholesterol, LDL-C and triglycerides. Thyroid hormone (TH) affects the production, clearance and transformation of cholesterol, but current research shows that thyroid-stimulating hormone (TSH) also participates in lipid metabolism independently of TH.
Huixing Liu, Daoquan Peng
openaire   +2 more sources

Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity

Scientific Reports, 2017
We investigated simultaneously traditional and novel lipid indices, alone or in combination, in predicting coronary severity assessed by Gensini score (GS) in 1605 non-lipid-lowering-drug-treated patients undergoing coronary angiography.
Sha Li, Yuan-Lin Guo, Xi Zhao, Yan Zhang, Cheng-Gang Zhu, Na-Qiong Wu, Rui-Xia Xu, Ping Qing, Ying Gao, Xiao-Lin Li, Jing Sun, Geng Liu, Qian Dong, Jian-Jun Li   +13 more
doaj   +1 more source

Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers

Lipids in Health and Disease, 2018
Background Achievement of low-density lipoprotein cholesterol (LDL-C) goal is the most important for the patients with atherosclerotic cardiovascular diseases (ASCVD) who received lipid-lowering therapy.
Na-Qiong Wu, Yuan-Lin Guo, Cheng-Gang Zhu, Ying Gao, Xi Zhao, Di Sun, Jing Sun, Rui-Xia Xu, Geng Liu, Qian Dong, Jian-Jun Li   +10 more
doaj   +1 more source

Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status

Cardiovascular Diabetology, 2019
Background The aim of the present study is to examine the effects of free fatty acids (FFAs) on major cardiovascular events (MACEs) in patients with stable coronary artery disease (CAD) and different glucose metabolism status.
Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Hui-Wen Zhang, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Rui-Xia Xu, Ying Gao, Jing Sun, Qian Dong, Jian-Jun Li   +11 more
doaj   +1 more source